Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Addex Therapeutics (ADXN) Operating Leases (2018 - 2025)

Addex Therapeutics' Operating Leases history spans 8 years, with the latest figure at $33791.6 for Q4 2025.

  • On a quarterly basis, Operating Leases fell 29.51% to $33791.6 in Q4 2025 year-over-year; TTM through Dec 2025 was $33791.6, a 29.51% decrease, with the full-year FY2025 number at $32575.1, down 32.05% from a year prior.
  • Operating Leases came in at $33791.6 for Q4 2025, down from $36208.2 in the prior quarter.
  • The five-year high for Operating Leases was $522745.2 in Q4 2021, with the low at $21883.7 in Q2 2024.
  • Historically, Operating Leases has averaged $140926.7 across 5 years, with a median of $72856.0 in 2022.
  • Biggest five-year swings in Operating Leases: soared 329.95% in 2021 and later tumbled 87.65% in 2024.
  • Year by year, Operating Leases stood at $522745.2 in 2021, then decreased by 25.91% to $387322.3 in 2022, then increased by 0.22% to $388188.7 in 2023, then plummeted by 87.65% to $47937.1 in 2024, then decreased by 29.51% to $33791.6 in 2025.
  • Business Quant data shows Operating Leases for ADXN at $33791.6 in Q4 2025, $36208.2 in Q3 2025, and $37319.0 in Q2 2025.